Golpimec (Fingolimod)

Golpimec is indicated for the treatment of relapsing‑remitting multiple sclerosis (RRMS) and is used as a disease‑modifying therapy to reduce the frequency of clinical relapses.

• Reduces the annualized relapse rate in patients with RRMS.
• Delays accumulation of disability as measured by the Expanded Disability Status Scale.
• May be prescribed as first‑line or escalation therapy depending on disease activity.
• Administered once daily as an oral capsule.
• Used together with regular neurologic monitoring and MRI assessments.

The safety profile of Golpimec includes a range of observed adverse events, which are categorized by frequency and clinical significance.

Common

• Headache, fatigue, and nasopharyngitis.
• Diarrhea or abdominal pain.
• Elevated liver enzymes (ALT/AST).
• Decreased peripheral blood lymphocyte count.

Serious

• Severe infections such as herpes zoster or opportunistic pathogens.
• Cardiac conduction abnormalities, including bradycardia or atrioventricular block.
• Macular edema leading to visual disturbances.

Before initiating Golpimec, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate patient selection.

• Baseline cardiac assessment, including ECG, for patients with a history of heart disease.
• Screening for active infections, especially varicella‑zoster virus, prior to treatment.
• Liver function tests should be normal or only mildly elevated before starting therapy.
• Pregnancy status must be confirmed; Golpimec is contraindicated in pregnancy.
• Patients should be monitored for signs of macular edema with regular ophthalmologic exams.
• Vaccinations, particularly live vaccines, should be administered at least 4 weeks before therapy.

Golpimec may interact with other medicines, and certain combinations should be avoided or used with caution.

Avoid

• Concurrent use of strong CYP4F2 inhibitors, which can increase fingolimod exposure.
• Combination with other immunosuppressive agents that markedly lower lymphocyte counts.
• Live vaccines administered during treatment, due to reduced immune response.

Use with caution

• Beta‑blockers or calcium‑channel blockers that affect heart rate; monitor cardiac function.
• Antiplatelet or anticoagulant drugs, as fingolimod may increase bleeding risk.